Furthermore, the effect in vivo of genetically modified monocytes for the release of IFNα into a mammary immunocompetent cancer model demonstrated increased infiltration of myeloid CD4 + and CD8 + T cells in the tumor microenvironment (TME) and decreased tumor burden [26]. The gene discussed is CD8A; the disease is neoplasm.